YZYifan Zhao

Yifan Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yifan Zhao has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Yi Zhang

    Department of Cardiology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China

    7 shared publications
  • Moran Li

    Heart Center, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China

    3 shared publications
  • Shikai Yu

    Department of Cardiology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China

    3 shared publications
  • Yawei Xu

    Department of Cardiology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China

    3 shared publications
  • Yawei Xu

    Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China

    3 shared publications
  • Haotian Yang

    Department of Cardiology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine , Shanghai

    2 shared publications

Latest Publications

  • Open Access

    Subendocardial Viability Ratio Is Associated With Target Organ Damage and Hints at a Potential Independent Predictor of Cardiovascular Mortality in Older Adults: A Prospective Cohort Study

    by Jun Han, JiaMin Tang, Yifan Zhao, Jing Xiong, Song Zhao, WenHui Yue, YaWei Xu, ShiKai Yu, Yi Zhang, Northern Shanghai Study

    Background: The subendocardial viability ratio (SEVR) reflects myocardial perfusion relative to workload. This study explored the association of SEVR with mortality and subclinical target organ damage in an older adult population. Methods: We analyzed the data from the Northern Shanghai Study, a community‐based cohort of older adults aged over 65 years. SEVR was measured with arterial tonometry. Cross‐sectional associations were assessed between SEVR levels and target organ damage (including arterial stiffness, peripheral artery disease, carotid plaque, left ventricular hypertrophy, left ventricular diastolic dysfunction, chronic kidney dysfunction, and microalbuminuria). Longitudinal associations between SEVR and mortality were evaluated using Cox and Fine‐Gray models. Results: Among 3237 participants (mean age 71±6 years, 57% female), 233 deaths occurred over a median follow‐up of 5.7 years, including 94 cardiovascular deaths. Participants were divided into 2 groups by the median value of SEVR (129%). The group with a lower SEVR (≤129%) was associated with higher risk of cardiovascular death (adjusted Cox Hazard Ratio [HR]=1.70 [1.05–2.75]; P =0.03), but not with all‐cause death (adjusted Cox HR=1.30 [0.98–1.73]; P =0.07). As for target organ damage, participants with more damaged organs had lower SEVR values ( P for trend P P <0.001, respectively. Conclusions: Lower SEVR is independently associated with both increased cardiovascular mortality and organ damage, including arterial stiffness and left ventricular diastolic dysfunction in older adult populations. SEVR may be a convenient marker for early cardiovascular risk stratification in aging populations. Registration: URL: https://ClinicalTrial.gov ; Unique Identifier: NCT02368938.


  • Open Access

    Association between novel Immune-Inflammatory markers and hypertension patients with coronary heart disease: A Cross-Sectional study based on NHANES (2005–2016)

    by Ruiyuan Li, Aili Atawula, Haonan Li, Moran Li, Jiamin Tang, Jie Liu, Jieying Shi, Jingjing Hou, Feng Hai, Yifan Zhao, et al.

    This study aims to investigate novel inflammatory markers, including the systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), and aggregate inflammatory score index (AISI), and their relationship with coronary heart disease (CHD) in patients with hypertension (HT) using data from the National Health and Nutrition Examination Survey (NHANES). We conducted a cross-sectional study using complete data from the 2005–2016 NHANES survey. A total of 9,242 hypertensive participants aged 18 years or older were included in the study. Participants were divided into HT group and HT combined with CHD group. SII was calculated as PC × NC/LC, SIRI was calculated as NC × MC/LC, and AISI was calculated as MC × PC × NC/LC. Additionally, demographic, lifestyle factors and health-related information was gathered. Logistic regression models were utilized to pinpoint SII, SIRI, and AISI associated with HT combined with CHD, and constructed three nomogram models to forecast HT combined with CHD risk. In our cohort of 9,242 patients, 2,055 (30.77%) had CHD. Higher levels of log2-SII (OR 1.10, 95%CI: 1.03–1.17, P = 0.003), log2-SIRI (OR 1.27, 95%CI: 1.19–1.35, P < 0.001) and log2-AISI (OR 1.13, 95%CI: 1.07–1.19, P < 0.001) were associated with an increased likelihood of CHD in hypertensive patients. Elevated log2-SII, log2-SIRI, and log2-AISI, along with male gender, older age, non-Mexican American ethnicity, family poverty income ratio (PIR) < 1.5, and smoking, were identified as risk factors for CHD in hypertensive populations. Calibration curves were constructed to assess the deviation between predicted and actual values, with 1,000 bootstrap iterations showing good consistency between predictions and observed outcomes. AUC values of the three models were 0.724 (95% CI: 0.712–0.736), 0.730 (95% CI: 0.718–0.741), and 0.726 (95% CI: 0.714–0.737), respectively. All the three models had good discrimination power. Decision curve analysis indicated that all three nomogram models are effective in clinical practice. These novel immune-inflammatory markers (SII, AISI, SIRI) offer a simple, non-invasive, and cost-effective screening tool with promising clinical application for predicting CHD risk in HT population. They have the potential to guide personalized treatment, aligning with the goals of precision medicine.


  • Open Access

    Establishment and validation of an artificial intelligence-based system for identifying the culprit vessel in patients with ST-segment elevated myocardial infarction: the ALERT study

    by Qiaorui He, Yang Hou, Xiao Xu, Jinlei Li, Xianxian Zhao, Yawei Xu, Yi Zhang, Yifan Zhao

    Objective: The inaccurate identification of the culprit vessel is a critical issue in the treatment of patients with ST-segment elevated myocardial infarction (STEMI). This study aimed to establish an artificial intelligence (AI)-based algorithm for the culprit vessel identification in patients with STEMI. Methods and analysis: 698 ECGs were conducted within 12 hours before primary percutaneous coronary intervention from patients with STEMI. The internal training and testing sets consisted of 543 ECGs collected from two tertiary hospitals, and the external validation set consisted of 155 ECGs collected from another independent tertiary hospital. These ECGs represented STEMI patients with various culprit vessels, such as left anterior descending artery (LAD), right coronary artery (RCA) and left circumflex artery (LCX), validated by further coronary angiography (CAG). Results: Among 698 patients (mean (SD) age, 71.1 (11.3) years), the culprit vessels were LAD in 328, RCA in 288 and LCX in 82. In the internal training, an algorithm was developed (LAD: sensitivity 92.4%, specificity 99.7%; RCA: sensitivity 93.2%, specificity 97.4%; LCX: sensitivity 99.7%, specificity 95.8%). Internal testing revealed that it achieved high performance metrics (LAD: sensitivity 91.6%, specificity 96.0%; RCA: sensitivity 75.1%, specificity 95.8%; LCX: sensitivity 97.0%, specificity 88.8%), outperforming cardiologists and commercial algorithm. In the external validation, it also demonstrated competitive performance (LAD: sensitivity 72.0%, specificity 94.3%; RCA: sensitivity 90.5%, specificity 92.4%; LCX: sensitivity 92.9%, specificity 91.2%). Conclusion: We established and validated an AI-based algorithm for the culprit vessel identification in patients with STEMI, comparable to experienced cardiologists. The generalisability of our algorithm on a global scale needs further verification. Trial registration number: NCT03317691.


  • Open Access

    Association of Baseline eGFR and Incident Heart Failure On Patients Receiving Intensive Blood Pressure Treatment

    by Li Haonan, He Qiaorui, Zhu Wenqing, Zhang Yanjun, Pingcuo Wangjia, Yu Shikai, Deji Zhuoga, Zhang Yi, Zhao Yifan

    Aims: We aim to elucidate the association of baseline eGFR and incident heart failure on patients receiving intensive BP treatment. Methods and results: A post hoc analysis was conducted on the SPRINT database. Multivariab le Cox regression and interaction restricted cubic spline (RCS) analysis were performed to investigate the interaction between baseline eGFR and intensive BP control on heart failure prevention. The primary endpoint focused on incident heart failure. The study cohort comprised 8369 adults with a mean [SD] age of 68 [59–77] years, including 2940 women (35.1%). Over a median [IQR] follow-up period of 3.9 [2.0–5.0] years, 183 heart failure events were recorded. A significant interaction was observed between baseline eGFR and treatment groups in terms of heart failure prevention (Interaction P = 0.012). The risk of heart failure showed a sharp slope until eGFR = 75 mL/min/1.73 m2 and then became flat by an interaction RCS. Intensive BP treatment did not exhibit a preventive effect on heart failure (HR (95% CI) = 1.03 (0.82–1.52)) when baseline eGFR was 75 mL/min/1.73 m2 or lower. Conversely, when baseline eGFR was higher than 75 mL/min/1.73 m2, a reduced risk of heart failure was observed (HR (95% CI) = 0.65 (0.41–0.98)). Intensive BP control did not increase the incident long-term dialysis regardless of baseline eGFR but was associated with a higher risk of eGFR reduction. Conclusions: Among nondiabetic hypertensive patients, baseline eGFR serves as a crucial indicator for assessing the risk reduction potential of intensive BP control in heart failure prevention, with 75 mL/min/1.73 m2 appearing as a suitable cut-off value.


  • Open Access

    Association Between Systolic Blood Pressure Time in Target Range Indices and Adverse Cardiovascular Outcomes

    by Moran Li, Song Zhao, Shikai Yu, Rusitanmujiang Maimaitiaili, Yawei Xu, Yan Li, Yifan Zhao, Yi Zhang


  • Open Access

    Vasculopathy Augments Cardiovascular Risk in Community-Dwelling Elderly with Left Ventricular Hypertrophy

    by Rusitanmujiang Maimaitiaili, Song Zhao, Jiadela Teliewubai, Shikai Yu, Weilun Meng, Yifan Zhao, Yawei Xu, Yi Zhang

    This study aimed to investigate the impact of various vasculopathies alongside left ventricular hypertrophy (LVH) on cardiovascular risk in the elderly. This prospective cohort study included 3339 older adults from the Northern Shanghai Study, classified into four mutually exclusive left ventricular (LV) geometry groups based on echocardiographic data: normal geometry, concentric remodeling, eccentric hypertrophy, and concentric hypertrophy. Vasculopathy was categorized into three primary types: arteriosclerosis, atherosclerosis, and renal senescence. Major adverse cardiovascular events (MACEs) were defined as non-fatal acute myocardial infarction, non-fatal stroke, and cardiovascular deaths according to ICD-10 codes. Over a median follow-up period of 5.7 years, 221 incident cases of MACEs were identified. Concentric hypertrophy exhibited the highest prevalence of hypertension, the most significant increase in vascular stiffness, and the highest rate of MACEs. The adjusted Cox regression analysis showed that eccentric hypertrophy is associated with an increased risk of MACEs (HR: 1.638 [95% CI: 1.151–2.331], p = 0.006), while concentric hypertrophy shows an even higher risk (HR: 1.751 [95% CI: 1.127–2.721], p = 0.013). Conversely, concentric remodeling was not significantly associated with an increased risk of MACEs. Renal senescence presents a moderate but significant risk for MACEs, with an HR of 1.361 (95% CI: 1.019–1.819; p = 0.037) when adjusted for LVH. The Kaplan–Meier analysis showed that patients with LVH and multiple vasculopathies experience the most significant decrease in survival probability (log-rank p < 0.001). The subgroup analysis revealed that LVH significantly raises the risk of MACEs, especially in older males with hypertension, diabetes, or vasculopathy. This study reinforces the importance of LVH as a predictor of adverse cardiovascular outcomes and underscores the compounded risk associated with the presence of multiple vasculopathies. Additionally, it highlights renal senescence as a distinct and independent risk factor for MACEs, separate from LVH.

  • Open Access

    Age and blood pressure stratified healthy vascular aging, organ damage and prognosis in the community-dwelling elderly: insights from the North Shanghai Study

    by Zhongyuan Ren, Haotian Yang, Wenqing Zhu, Jun Han, Shikai Yu, Song Zhao, Weilun Meng, Yawei Xu, Yifan Zhao, Yi Zhang

    This study aimed to investigate the prognostic value of age and blood pressure stratified healthy vascular aging (HVA) defined in the North Shanghai Study (NSS), and illustrate its relationship with organ damage (OD). This study enrolled 3590 community-dwelling elderly Chinese aged over 65 years and finally 3234 participants were included. 3230 individuals were included in the final analysis, with 4 participants lost to follow-up. NSS HVA was defined as low carotid-femoral pulse wave velocity (PWV) which had a higher cutoff value with advanced age and level of blood pressure. OD was thoroughly assessed and classified into vascular, cardiac and renal OD. Primary endpoints were major adverse cerebrocardiovascular events (MACCE) and all-cause mortality. Nine hundred seventy-eight participants out of 3234 participants (43.1%) were identified as having NSS HVA. The NSS HVA group exhibited a younger age, lower blood pressure levels, lower body mass index, and milder OD compared to the non-NSS HVA group. Over follow-up of 5.7 ± 1.8 years, 332 MACCE (1.82 per 100 person-year) and 212 all-cause deaths (1.14 per 100 person -year) occurred. NSS HVA was associated with a reduced risk of MACCE (HR [95% CI] = 0.585, 0.454–0.754) and all-cause death (HR [95%CI] = 0.608 [0.445, 0.832]), especially in those subgroups without clinical diagnosed cardiovascular disease (CVD) or diabetes mellitus but with at least one type of OD. Moreover, NSS HVA exhibited improved prognostic value for MACCE, all-cause death and CVD death compared to other definitions of HVA. Age and blood pressure stratified NSS HVA could serve as an improved indicator against serious adverse events in the community-dwelling elderly Chinese. Prognosis in the Elderly Chinese: The Northern Shanghai Study (NSS), NCT02368938, https://clinicaltrials.gov/study/NCT02368938?cond=NCT02368938&rank=1 .

  • Open Access

    ASSOCIATION OF HIGH NORMAL BLOOD PRESSURE DEFINED BY DIFFERENT CRITERIA WITH ALL-CAUSE AND CARDIOVASCULAR MORTALITY

    by Yifan Zhao, Moran Li, Yi Zhang, Jun Han

    Objective: To evaluate the association of the all-cause and cardiovascular mortality with the guideline-based classification criteria and systolic blood pressure (SBP)-based classification for high normal blood pressure. Design and method: We collected data from the NHANES Database,which is a large, serial, cross-sectional survey designed to be nationally representative of the civilian adult population in the United States Inclusion Criteria: SBP > 90mmHg; Without any antihypertensive treatment; Having complete record for a history of major cardiovascular-related disease including hypertension, coronary heart disease, myocardial infarction, heart failure, stroke, diabetes and hyperlipemia. All the participants were divided into 3 groups according to the latest guidelines or systolic blood pressure. Group1: Normotensivel; Group2: High normal blood pressure; Group3: Hypertension Results: By grouping population according to guideline definition, in terms of all-cause mortality and cardiovascular death, there was no significant difference between population with normal blood pressure (NT) and with high normal blood pressure (HNBP). But both groups had significantly lower risk compared with hypertension group (HTN). Multivariate Cox regression results indicated the lowest risk of all-cause mortality in the HNBP group and no difference in risk of all-cause mortality between the NT and HTN groups, which was illogical and inconsistent with real-world clinical practice. By grouping population according to SBP, we found that the grouping better distinguished all-cause and cardiovascular mortality among groups. Multivariate COX regression analysis found that NT and HNBP groups had no difference in risk of all-cause and cardiovascular death. The restricted cubic spline curve of DBP showed the lowest HR were found when DBP was between 83 and 95 mmHg, which were defined as high normal blood pressure or hypertension according to guideline-directed classification. This result may be the primary reason for the difference between guideline and SBP-directed classification. Conclusions: In this study, our analysis showed that the blood pressure based on SBP had a higher association with both all-cause mortality and cardiovascular mortality than the guide-directed definition. DBP inclusion could be a confounding factor for the classification. People with high normal blood pressure did not show a worse prognosis than those with normal blood pressure.

  • Open Access

    Etiological Diagnosis and Personalized Therapy for Hypertension: A Hypothesis of the REASOH Classification

    by Chong Xu, Moran Li, Weilun Meng, Jun Han, Song Zhao, Jiamin Tang, Haotian Yang, Rusitanmujiang Maimaitiaili, Jiadela Teliewubai, Shikai Yu, et al.

    With the epidemic of risk factors such as unhealthy lifestyle, obesity and mental stress, the prevalence of hypertension continues to rise across the world. Although standardized treatment protocols simplify the selection of antihypertensive drugs and ensure therapeutic efficacy, the pathophysiological state of some patients remains, which may also lead to the development of other cardiovascular diseases. Thus, there is an urgent need to consider the pathogenesis and selection of antihypertensive drug for different type of hypertensive patients in the era of precision medicine. We proposed the REASOH classification, based on the etiology of hypertension, including renin-dependent hypertension, elderly-arteriosclerosis-based hypertension, sympathetic-active hypertension, secondary hypertension, salt-sensitive hypertension and hyperhomocysteinemia hypertension. The aim of this paper is to propose a hypothesis and provide a brief reference for the personalized treatment of hypertensive patients.